Send us a text

This week, Amol and Reena, internist at St. Michael’s hospital in Toronto, discuss the HOPE-3 trial. HOPE-3 is a 2-by-2 double blind randomized placebo controlled trial, which found that statins were effective in preventing cardiovascular events in intermediate risk patients but anti-hypertensives were not. While candesartan and hydrochlorothiazide were not superior to placebo, rosuvastatin resulted ...

The post A New HOPE: Statins and Anti-hypertensives in intermediate cardiovascular risk appeared first on Healthy Debate.